ArticleCancer research communications2024

ETx-22, a Novel Nectin-4-Directed Antibody-Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4-Expressing Tumors.

Marc Lopez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.